Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Micardis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Micardis was produced by Boehringer Ingelheim and Astellas.

Boehringer Ingelheim returns to growth after US turnaround

Boehringer Ingelheim returns to growth after US turnaround

Boehringer's heart drug Micardis (telmisartan) continued to suffer the effects of generic competition, with sales down 12.1% to 956m, but 2015 also saw the company's diabetes portfolio making

Humira remains top pharma product, but Sovaldi closes in

Humira remains top pharma product, but Sovaldi closes in Boehringer has seen a similar situation with its heart drug Micardis(telmisartan) that has been losing patent protection for over a year.

Heart drug sales continue downward spiral

Heart drug sales continue downward spiral Finally Boehringer, which saw the largest drop in the top ten table due predominately to the patent loss of Micardis (telmisartan).

Boehringer's sales drop after 'intense and challenging' year

Boehringer's sales drop after 'intense and challenging' year During the year all four of Boehringer's top products saw their global sales decline, most noticeably cardiovascular drug Micardis (telmisartan) and COPD treatment Combivent (ipratropium and albuterol), both of which

Micardis

Micardis campaign. Created by Seven Stones for Boehringer Ingelheim. Therapy area: Cardiovascular

1 2 3 [ Next 5 results ]

Subscribe to our email news alerts

PMHub

Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...